European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Take Home Message The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available s...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2016-11, Vol.70 (5), p.705-706
Main Authors: Powles, Thomas, Staehler, Michael, Ljungberg, Börje, Bensalah, Karim, Canfield, Steven E, Dabestani, Saeed, Giles, Rachel H, Hofmann, Fabian, Hora, Milan, Kuczyk, Markus A, Lam, Thomas, Marconi, Lorenzo, Merseburger, Axel S, Volpe, Alessandro, Bex, Axel
Format: Article
Language:English
Subjects:
Anilides - administration & dosage
Antibodies, Monoclonal - administration & dosage
Antineoplastic Agents - administration & dosage
Cabozantinib
Carcinoma, Renal Cell - drug therapy
European Association of Urology
Guidelines
Humans
Nivolumab
Pyridines - administration & dosage
Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors
Renal cancer
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Take Home Message The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.
ISSN:0302-2838
1873-7560
1873-7560
DOI:10.1016/j.eururo.2016.06.009